Ligustrazine alleviates the progression of coronary artery calcification by inhibiting caspase-3/GSDME mediated pyroptosis
BioScience Trends · 2024
DOI: 10.5582/bst.2024.01096 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioScience Trends, 2024. Verfasst von Honghui Yang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhengzhou University, Central China Fuwai Hospital, Zhengzhou, China. Hauptthemen laut MEDLINE: Pyroptosis, Pyrazines, Caspase 3, Vascular Calcification. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhengzhou University, Central China Fuwai Hospital, Zhengzhou, China.
Zitieren
APA
Yang, H., Xu, G., Li, Q., & Zhu, L. (2024). Ligustrazine alleviates the progression of coronary artery calcification by inhibiting caspase-3/GSDME mediated pyroptosis. BioScience Trends. https://doi.org/10.5582/bst.2024.01096
Vancouver
Yang H, Xu G, Li Q, Zhu L. Ligustrazine alleviates the progression of coronary artery calcification by inhibiting caspase-3/GSDME mediated pyroptosis. BioScience Trends. 2024. doi:10.5582/bst.2024.01096
BibTeX
@article{Yang2024,
author = {Yang, Honghui and Xu, Guian and Li, Qingman and Zhu, Lijie},
title = {Ligustrazine alleviates the progression of coronary artery calcification by inhibiting caspase-3/GSDME mediated pyroptosis},
journal = {BioScience Trends},
year = {2024},
doi = {10.5582/bst.2024.01096}
}
EUVIMED